Multiple Myeloma
10
Companies
15
Drug Programs
3
Phase 3
0
Upcoming PDUFAs
Sanofi
Sarclisa
Bristol Myers Squibb
Zenbexus
Sanofi
isatuximab-irfc
Biogen
felzartamab
Bristol Myers Squibb
iberdomide
Johnson & Johnson
Thalidomide
AbbVie
etentamig
Johnson & Johnson
Vincristine, DOXIL (doxorubicin HCl liposomal injection), and Dexamethasone (VDD) vs. Vincristine, Doxorubicin and Dexamethasone (VAD)
Incyte Corporation
Ruxolitinib 25 mg
Geron Corporation
Imetelstat (7.5 mg/kg)
Bristol-Myers Squibb Company
Arlocabtagene Autoleucel
Regeneron Pharmaceuticals, Inc.
REGN5458
Juno Therapeutics
cilta-cel
Celgene
iberdomide
Dyax Pharma
CAR T Cell Therapy
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| SNY Sanofi | Sarclisa | Approved | — | — | — |
| BMY Bristol Myers Squibb | Zenbexus | Approved | — | — | — |
| SNY Sanofi | isatuximab-irfc | Approved | — | — | — |
| BIIB Biogen | felzartamab | Approved | — | — | — |
| BMY Bristol Myers Squibb | iberdomide | Approved | — | — | — |
| JNJ Johnson & Johnson | Thalidomide | Phase 3 | — | — | — |
| ABBV AbbVie | etentamig | Phase 3 | — | — | — |
| JNJ Johnson & Johnson | Vincristine, DOXIL (doxorubicin HCl liposomal injection), and Dexamethasone (VDD) vs. Vincristine, Doxorubicin and Dexamethasone (VAD) | Phase 3 | — | — | — |
| INCY Incyte Corporation | Ruxolitinib 25 mg | Phase 2 | — | — | — |
| GERN Geron Corporation | Imetelstat (7.5 mg/kg) | Phase 2 | — | — | — |
| BMY Bristol-Myers Squibb Company | Arlocabtagene Autoleucel | Phase 2 | — | — | — |
| REGN Regeneron Pharmaceuticals, Inc. | REGN5458 | Phase 2 | BTFTOD | — | — |
| BMY Juno Therapeutics | cilta-cel | — | — | — | — |
| CELG Celgene | iberdomide | — | — | — | — |
| DFPH Dyax Pharma | CAR T Cell Therapy | — | — | — | — |
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.